

ASX ANNOUNCEMENT

11 June 2021

UK Market update, wheezo® Registered and Approved for Sale in the UK Market

Respiri Limited (ASX:RSH) (“Respiri” or the “Company”), an eHealth SaaS Company supporting respiratory health management, today announces that, ahead of required timelines, wheezo® is now registered and approved for sale in the UK market following its registration with the UK Competent Authority, the Medicines and Healthcare Products Regulatory Agency (MHRA).

As per MHRA requirements, the Company appointed European Device Solutions (UK) Ltd as the UK Responsible Person (UK-RP) and has demonstrated that wheezo® will perform safely and achieve the stated performance claims for its intended use. As a result, the Company can now apply the new UK Conformity Assessed (UKCA) mark on wheezo®.

UKCA marking is a new UK product marking that is used for goods being placed on the market in Great Britain (England, Scotland and Wales). It is a prerequisite for the approval of products following Brexit and indicates conformity with applicable regulatory requirements. UKCA replaces CE marking, which can still be used in the UK until 31 December 2021 for products that are currently being sold in the UK but CE cannot be used for any products that have not been sold in the UK market after January 1, 2021. Accordingly, this process fulfils a commercial requirement for wheezo®, which is due to be launched in the UK in Q4 CY 2021.

“Respiri has been in ongoing planning discussions and negotiations with potential commercial and distribution partners in the UK as it readies for the planned launch in Q4 CY2021. The UKCA marking for wheezo® is another accomplishment for Respiri; the final regulatory requirement that now permits Respiri to commence commercialising wheezo® in the UK in Q4 CY2021, as planned” said Marjan Mikel, CEO of Respiri.

It is important to note that asthma exacerbation is the 3rd major cause of hospitalisations in the UK and the most common reason for re-hospitalisation, resulting from poorly controlled and managed asthma. “Given the high incidence of hospitalisation resulting from poorly controlled, asthma we are pleased that wheezo® has been chosen as a technology of choice by a number of prominent UK Universities to study its impact on improving patient asthma management and we will keep the market informed of these developments”, reinforced Mr Mikel.

Asthma represents a significant disease burden in the UK with 5.4 million people currently receiving treatment for their condition, and the NHS spending around £1 Billion GBP per annum, treating and caring for people with asthma¹. Asthma UK believe that digital health technology has a significant role to play in helping people better manage their condition² and in 2016 published the Connected Asthma Report, highlighting how asthma is ideally placed to be transformed by technology³.”

For further information about wheezo®, follow the online link <https://wheezo.com>

- ENDS -

¹ Asthma UK <https://www.asthma.org.uk/about/media/facts-and-statistics/>

² Asthma UK <https://www.asthma.org.uk/for-professionals/asthma-digital-health/>

³ Asthma UK <https://www.asthma.org.uk/support-us/campaigns/our-policy-work/asthma-needs-research/connected-asthma/>

For further information, investors and media please contact:

Mr Marjan Mikel
CEO & Managing Director
Respiri Limited
P: +61 408 462 873
E: marjan@respiri.co

Mr Nicholas Smedley
Executive Chairman
Respiri Limited
P: +61 447 074 160
E: nicholas@respiri.co

wheezo® is a Registered Trademark of Respiri Limited.

This ASX announcement dated 11 June 2021 has been authorised for release by the Board of Directors of Respiri Limited.

About Respiri Limited

Respiri is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. wheezo®, Respiri's innovative technology, comprises an eHealth app combined with a simple, easy to use, handheld device. wheezo® is the first smart device to assist with asthma management by monitoring wheeze and documenting symptoms, signs, triggers, weather conditions and medication use. The platform also facilitates the sharing of data with caregivers, physicians, and other health care professionals.

Respiri's mission is to improve asthma management by extending care beyond the clinic.

For additional information about Respiri and its products, please visit www.respiri.co

About wheezo®

Developed in Australia, with the support of respiratory specialists and other healthcare professionals, the innovative wheezo® device analyses breath sounds for wheeze, and the eHealth App assists patients with managing their asthma by tracking symptoms, triggers, medication use and geo-specific weather conditions. The platform has been designed to extend asthma management beyond the clinic and make it easy to share information with doctors and make appropriate adjustments to asthma action plans. Better active management may lead to better outcomes and improved quality of life for the asthma patient.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respiri current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respiri only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.